Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 8/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403095 | 0.79 | PDPK1 (0.47) | ALDH1A1PDPK1PARP1DAPK3PRKD3 | |
| SCHEMBL16384769 | 0.74 | ALDH1A1 (0.45) | ALDH1A1PDPK1PARP1DAPK3PRKD3 | |
| SCHEMBL725336 | 0.73 | KDM4E (0.33) | ALDH1A1PDPK1KDRNPC1RAB9A | |
| SCHEMBL20489502 | 0.71 | KDR (0.40) | ALDH1A1KDRPARP1PIM1CDC7 | |
| SCHEMBL8818264 | 0.70 | ALDH1A1 (0.41) | ALDH1A1PDPK1PARP1DAPK3PRKD3 | |
| SCHEMBL20752274 | 0.67 | KDR (0.42) | ALDH1A1KDRCDC7NPC1RAB9A | |
| SCHEMBL20489472 | 0.67 | PIM1 (0.40) | ALDH1A1KDRPIM1SMN1; SMN2HPGD | |
| SCHEMBL20489427 | 0.67 | KDR (0.36) | KDR | |
| SCHEMBL6119366 | 0.67 | PDPK1 (0.58) | ALDH1A1PDPK1PARP1PIM1PIM3 | |
| SCHEMBL21206677 | 0.66 | KDR (0.41) | ALDH1A1KDRIKBKBAURKANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4532495-A1 | CD73 INHIBITOR COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| CN-119585273-A | CD73 inhibitor compounds | 阿道尔克斯治疗有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240366612-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024228132-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-11-07 | — | — | WO | disclosed |
| US-20240279239-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4416156-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023233130-A1 | CD73 INHIBITOR COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2023-12-07 | — | — | WO | disclosed |
| CN-116134036-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2012066578-A2 | SUBSTITUTED 4-(SELENOPHEN-2(OR 3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-05-24 | — | — | WO | disclosed |
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| EP-1912639-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366612-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | ALDH1A1 3447/4885PDPK1 2464/4885KDR 4140/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | ALDH1A1 682/4885PDPK1 1570/4885KDR 3517/4885 |
| US-20240279239-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | ALDH1A1 3559/4885PDPK1 2136/4885KDR 4248/4885 |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | ABL1, MAP3K19, PI4KB | ALDH1A1 2812/4885PDPK1 33/4885KDR 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.